Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Zachary N. Warnken has a total of 90 co-authors. Here are the top co-authors by number of shared publications:

  • Robert O. Williams

    Division of Molecular Pharmaceutics and Drug Delivery, College of Pharmacy, The University of Texas at Austin, Austin, TX 78712, USA

    14 shared publications
  • Miguel O. Jara

    Molecular Pharmaceutics and Drug Delivery Division, College of Pharmacy, The University of Texas at Austin, 2409 University Avenue, Austin, TX 78712, USA

    5 shared publications
  • Chaeho Moon

    Division of Molecular Pharmaceutics and Drug Delivery, College of Pharmacy, The University of Texas at Austin, Austin, TX 78712, USA

    4 shared publications
  • Esther Y. Maier

    Department of Chemistry, University of Texas at Austin , Austin, TX 78712

    4 shared publications
  • Haiyue Xu

    The University of Texas at Austin, College of Pharmacy, Division of Molecular Pharmaceutics and Drug Delivery, Austin, TX, United States

    3 shared publications
  • Hugh D. C. Smyth

    College of Pharmacy, Division of Molecular Pharmaceutics and Drug Delivery, The University of Texas at Austin, Austin, Texas 78712, United States

    3 shared publications

Latest Publications

  • Open Access

    Safety and Efficacy of Inhaled Natural Product Powders That Enhance Mucociliary Clearance

    by Dale J. Christensen, Zachary Warnken, Daria Stoltz, Matthew Beerman, Norman Amparado, Michael Grass, Nicholas Haft, Juan Sabater

    Mucociliary clearance is the lung's primary defense against inhaled pathogens and particulates, requiring optimal airway surface liquid hydration, mucus rheology, and coordinated ciliary beating. Diseases and pollutants disrupt these processes through altered ion transport, elevated pH and calcium, and goblet cell hyperplasia that leads to viscous mucus and airway obstruction. This process depends on chloride and bicarbonate secretion, nitric oxide-driven ciliary motility, and bronchodilation to maintain mucus fluidity and clearance. This study was conducted to determine if inhalable dry-powder formulations composed of natural pH-raising agents, calcium chelators, and supportive amino acids could be developed that was safe and rescued impaired mucociliary clearance. Inhalable powders produced by spray drying were developed and evaluated using in vitro studies in differentiated human airway cultures grown at an air-liquid interface before testing of formulations in an ovine model of impaired mucociliary clearance to determine efficacy and an inhalation toxicology study was conducted to evaluate safety of the final formulation. The powders demonstrated increased ciliary beat frequency, improved mucociliary clearance, preserved epithelial integrity, and minimal cytokine release in vitro, restored tracheal mucus velocity in a dose-dependent manner in sheep, and confirmed safety with an established a no observed adverse effect level of 2.32 mg/kg/day that provides a 11.6-fold safety margin over a human dose of 50 mg/day on a mg/g of lung weight basis. This scalable, inhaled formulation represents a novel strategy to support lung health by accelerating removal of inhaled microparticles and mitigating the respiratory impacts of worsening air pollution and climate change.

  • Open Access

    Atovaquone Targets Mitochondrial Metabolism and Enhances Radiosensitivity of Diffuse Intrinsic Pontine Glioma

    by Faiqa Mudassar, Kristina M. Cook, Zachary N. Warnken, Neha Bal, Joey Lai, Brian Gloss, Holly P. McEwen, Ryan J. Duchatel, Geraldine M. O’Neill, Harriet Gee, et al.

    Diffuse intrinsic pontine glioma (DIPG) is a lethal childhood brain tumor. Radiotherapy remains the standard of care, but tumors recur due to radioresistance. Tumor hypoxia contributes to radioresistance, and evidence of oxidative metabolism and hypoxia-associated transcriptomic programs suggests that hypoxia may be relevant in DIPG. We therefore investigated the FDA-approved mitochondrial inhibitor atovaquone as a strategy to target oxidative metabolism and enhance radiation response in DIPG. Methods: Patient-derived DIPG cell lines were used to evaluate atovaquone by extracellular flux analysis, hypoxia and reactive oxygen species assays, clonogenic survival assays, metabolomics, and RNA sequencing. To improve brain exposure, an amorphous solid dispersion (ASD) atovaquone formulation was evaluated and tested in an orthotopic DIPG model. Results: In patient-derived DIPG cultures, atovaquone suppressed mitochondrial respiration, reduced hypoxia-associated readouts, decreased HIF-1α expression in 3D models, and enhanced radiation response. At higher concentrations, atovaquone also increased oxidative stress and enhanced the radiosensitivity of DIPG monolayers. Transcriptomics analysis revealed disruption of cell-cycle and mitotic pathways, supporting additional treatment-associated effects beyond hypoxia reduction alone. Commercial and ASD formulations showed comparable in vitro activity. In vivo, ASD atovaquone combined with radiation prolonged survival in an orthotopic DIPG model. Conclusions: Targeting mitochondrial metabolism enhances radiosensitivity in DIPG and supports mitochondrial metabolism as a potential therapeutic weakness in this disease. Its effects are associated with reduced hypoxia-related signaling and broader metabolic and transcriptional changes.

  • Evaluating drug distribution in rat lung by mass spectrometry imaging after dry powder insufflation: Comparison of jet-milling, spray-drying, and thin film freezing

    by Chaeho Moon, Esther Y. Maier, Erin H. Seeley, Zachary N. Warnken, Beatriz Behrend-Keim, Sorawee Yanwinitchai, Mireya Mota, Robert O. Williams

  • Retraction
    Open Access

    RETRACTED: Khan et al. Poly (N-vinylcaprolactam-grafted-sodium alginate) Based Injectable pH/Thermo Responsive In Situ Forming Depot Hydrogels for Prolonged Controlled Anticancer Drug Delivery; In Vitro, In Vivo Characterization and Toxicity Evaluation. Pharmaceutics 2022, 14, 1050

    by Samiullah Khan, Muhammad Usman Minhas, Muhammad Tahir Aqeel, Ihsan Shah, Shahzeb Khan, Mohsin Kazi, Zachary N. Warnken

    The journal retracts the article, “Poly (N-vinylcaprolactam-grafted-sodium alginate) Based Injectable pH/Thermo Responsive In Situ Forming Depot Hy-drogels for Prolonged Controlled Anticancer Drug Delivery; In Vitro, In Vivo Characterization and Toxicity Evaluation”


  • Feasibility of intranasal delivery of thin-film freeze-dried, mucoadhesive vaccine powders

    by Yu-Sheng Yu, Khaled AboulFotouh, Haiyue Xu, Gerallt Williams, Julie Suman, Chris Cano, Zachary N. Warnken, Kevin C.-W. Wu, Robert O. Williams, Zhengrong Cui


  • Open Access

    Oral Delivery of Niclosamide as an Amorphous Solid Dispersion That Generates Amorphous Nanoparticles during Dissolution

    by Miguel O. Jara, Zachary N. Warnken, Sawittree Sahakijpijarn, Rishi Thakkar, Vineet R. Kulkarni, Dale J. Christensen, John J. Koleng, Robert O. Williams

    Niclosamide is an FDA-approved anthelmintic that is being studied in clinical trials as a chemotherapeutic and broad-spectrum antiviral. Additionally, several other applications are currently in the preclinical stage. Unfortunately, niclosamide is a poorly water soluble molecule, with reduced oral bioavailability, which hinders its use for new indications. Moreover, niclosamide is a poor glass former; in other words, the molecule has a high tendency to recrystallize, and it is virtually impossible to generate a stable amorphous solid employing the neat molecule. Previously, our group reported the development of an amorphous solid dispersion (ASD) of niclosamide (niclosamide ASD) that generates nanoparticles during its dissolution, not only increasing niclosamide’s apparent solubility from 6.6 ± 0.4 to 481.7 ± 22.2 µg/mL in fasted state simulated intestinal fluid (FaSSIF) but also its oral bioavailability 2.6-fold in Sprague–Dawley rats after being administered as a suspension. Nevertheless, niclosamide ASD undergoes recrystallization in acidic media, and an enteric oral dosage form is needed for its translation into the clinic. In this work, we further characterized the nanoparticles that generated during the dissolution of the niclosamide ASD. Cryogenic transmission electron microscopy (Cryo-TEM) and wide-angle X-ray scattering (WAXS) revealed that the nanoparticles were amorphous and had a particle size of ~150 nm. The oral dosage forms of niclosamide ASD were formulated using commercial enteric capsules (Capsuline® and EudracapTM) and as enteric-coated tablets. The enteric dosage forms were tested using pH-shift dissolution and acid-uptake tests, using the USP type II dissolution apparatus and the disintegration apparatus, respectively. The capsules exhibited a higher percentage of weight gain, and visual rupture of the Capsuline capsules was observed. Eudracap capsules protected the formulation from the acidic media, but polymer gelling and the formation of a nondispersible plug were noted during dissolution testing. In contrast, enteric-coated tablets protected the formulation from acid ingress and maintained the performance of niclosamide ASD granules during dissolution in FaSSIF media. These enteric-coated tablets were administered to beagle dogs at a niclosamide dose of 75 mg/kg, resulting in plasma concentrations of niclosamide higher than those reported in the literature using solubilized niclosamide at a higher dose (i.e., 100 mg/kg). In summary, an enteric oral dosage form of niclosamide ASD was formulated without hindering the generation of nanoparticles while maintaining the increase in the niclosamide’s apparent solubility. The enteric-coated tablets successfully increased the niclosamide plasma levels in dogs when compared to a niclosamide solution prepared using organic solvents.


  • Retracted
    Open Access

    RETRACTED: Poly (N-vinylcaprolactam-grafted-sodium alginate) Based Injectable pH/Thermo Responsive In Situ Forming Depot Hydrogels for Prolonged Controlled Anticancer Drug Delivery; In Vitro, In Vivo Characterization and Toxicity Evaluation

    by Samiullah Khan, Muhammad Usman Minhas, Muhammad Tahir Aqeel, Ihsan Shah, Shahzeb Khan, Mohsin Kazi, Zachary N. Warnken

    This study was aimed to develop novel in situ forming gels based on N-vinylcaprolactam, sodium alginate, and N,N-methylenebisacrylamide. The in situ Poly (NVRCL-g-NaAlg) gels were developed using the cold and free radical polymerization method. The structure formation, thermal stability, and porous nature of gels was confirmed by FTIR, NMR, DSC, TGA, and SEM. The tunable gelation temperature was evaluated by tube titling and rheological analysis. Optical transmittance showed that all formulations demonstrated phase transition around 33 °C. The swelling and release profile showed that gels offered maximum swelling and controlled 5-FU release at 25 °C and pH (7.4), owing to a relaxed state. Porosity and mesh size showed an effect on swelling and drug release. The in vitro degradation profile demonstrated a controlled degradation rate. An MTT assay confirmed that formulations are safe tested against Vero cells. In vitro cytotoxicity showed that 5-FU loaded gels have controlled cytotoxic potential against HeLa and MCF-7 cells (IC50 = 39.91 µg/mL and 46.82 µg/mL) compared to free 5-FU (IC50 = 50.52 µg/mL and 53.58 µg/mL). Histopathological study demonstrated no harmful effects of gels on major organs. The in vivo bioavailability in rabbits showed a controlled release in gel form (Cmax, 1433.59 ± 45.09 ng/mL) compared to a free drug (Cmax, 2263.31 ± 13.36 ng/mL) after the subcutaneous injection.


  • Open Access

    Innovating on Inhaled Bioequivalence: A Critical Analysis of the Current Limitations, Potential Solutions and Stakeholders of the Process

    by Jonattan Gallegos-Catalán, Zachary Warnken, Tania F. Bahamondez-Canas, Daniel Moraga-Espinoza

    Orally inhaled drug products (OIDPs) are an important group of medicines traditionally used to treat pulmonary diseases. Over the past decade, this trend has broadened, increasing their use in other conditions such as diabetes, expanding the interest in this administration route. Thus, the bioequivalence of OIDPs is more important than ever, aiming to increase access to affordable, safe and effective medicines, which translates into better public health policies. However, regulatory agencies leading the bioequivalence process are still deciding the best approach for ensuring a proposed inhalable product is bioequivalent. This lack of agreement translates into less cost-effective strategies to determine bioequivalence, discouraging innovation in this field. The Next-Generation Impactor (NGI) is an example of the slow pace at which the inhalation field evolves. The NGI was officially implemented in 2003, being the last equipment innovation for OIDP characterization. Even though it was a breakthrough in the field, it did not solve other deficiencies of the BE process such as dissolution rate analysis on physiologically relevant conditions, being the last attempt of transferring technology into the field. This review aims to reveal the steps required for innovation in the regulations defining the bioequivalence of OIDPs, elucidating the pitfalls of implementing new technologies in the current standards. To do so, we collected the opinion of experts from the literature to explain these trends, showing, for the first time, the stakeholders of the OIDP market. This review analyzes the stakeholders involved in the development, improvement and implementation of methodologies that can help assess bioequivalence between OIDPs. Additionally, it presents a list of methods potentially useful to overcome some of the current limitations of the bioequivalence standard methodologies. Finally, we review one of the most revolutionary approaches, the inhaled Biopharmaceutical Classification System (IBCs), which can help establish priorities and order in both the innovation process and in regulations for OIDPs.


  • Niclosamide inhalation powder made by thin-film freezing: Multi-dose tolerability and exposure in rats and pharmacokinetics in hamsters

    by Miguel O. Jara, Zachary N. Warnken, Sawittree Sahakijpijarn, Chaeho Moon, Esther Y. Maier, Dale J. Christensen, John J. Koleng, Jay I. Peters, Sarah D. Hackman Maier, Robert O. Williams Iii